Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Marc Matrana, Frank Tsai, Suma Satti, James Cleary, Jacob Estes, Khanh Do, Valentin Kolmakov, Takumi Kawabe, Geoffrey I. Shapiro | ||||||||||||
Title | Phase Ib clinical study of CBP501, cisplatin and nivolumab administered every 3 weeks in patients with advanced refractory tumors. Dose escalation cohort | ||||||||||||
|
|||||||||||||
URL | https://www.abstractsonline.com/pp8/#!/6812/presentation/10041 | ||||||||||||
Abstract Text | AACR Annual Meeting 2019, Abstract CT228 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | pancreatic cancer | predicted - sensitive | CBP501 + Cisplatin + Nivolumab | Case Reports/Case Series | Actionable | In a Phase Ib trial, CBP501, Platinol (cisplatin), and Opdivo (nivolumab) triple combination therapy resulted in partial response in a patient with CD274 (PD-L1)-positive (70% tumor cells) pancreatic cancer (AACR Annual Meeting 2019, Abstract CT228; NCT03113188). | detail... |